Trinity Biotech plc (TRIB), a commercial stage biotechnology company, Thursday announced a strategic collaboration with medical artificial intelligence company PulseAI to improve its recently acquired continuous glucose monitor biosensor technology.
Under this collaboration, Trinity Biotech will provide a pool of unique multi-parameter CGM datasets from Trinity Biotech's existing biosensor database to PulseAI. The data will be used to support the design and implementation of Trinity Biotech's AI-driven health & wellness analytics platform.
Trinity Biotech Chief Technology Officer, Dr Gary Keating, stated, "This collaboration will deliver important insights as we develop our AI driven analytical platform. This project will harness the potential of using additional personalised data from in, on and around the body to enhance the utility of continuous glucose measurements, improving the user experience, increasing satisfaction, and providing superior metabolic insights."
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.